1. Home
  2. GKOS vs UHS Comparison

GKOS vs UHS Comparison

Compare GKOS & UHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$177.33

Market Cap

10.9B

Sector

Health Care

ML Signal

N/A

Logo Universal Health Services Inc.

UHS

Universal Health Services Inc.

N/A

Current Price

$169.69

Market Cap

10.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GKOS
UHS
Founded
1998
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Hospital/Nursing Management
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9B
10.2B
IPO Year
2015
1994

Fundamental Metrics

Financial Performance
Metric
GKOS
UHS
Price
$177.33
$169.69
Analyst Decision
Strong Buy
Buy
Analyst Count
12
11
Target Price
$126.92
$216.36
AVG Volume (30 Days)
580.7K
554.8K
Earning Date
04-29-2026
04-27-2026
Dividend Yield
N/A
0.48%
EPS Growth
N/A
37.34
EPS
N/A
11.63
Revenue
$507,442,000.00
$17,364,829,000.00
Revenue This Year
$23.32
$7.67
Revenue Next Year
$27.43
$4.99
P/E Ratio
N/A
$14.67
Revenue Growth
32.33
9.71
52 Week Low
$73.16
$140.08
52 Week High
$191.62
$246.33

Technical Indicators

Market Signals
Indicator
GKOS
UHS
Relative Strength Index (RSI) 55.85 52.15
Support Level $175.04 $164.90
Resistance Level $184.00 $176.99
Average True Range (ATR) 5.63 4.54
MACD -1.97 -1.25
Stochastic Oscillator 30.42 31.31

Price Performance

Historical Comparison
GKOS
UHS

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About UHS Universal Health Services Inc.

Universal Health Services Inc offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the U.S, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.

Share on Social Networks: